Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01747824
Other study ID # 12-3478
Secondary ID
Status Completed
Phase N/A
First received December 4, 2012
Last updated December 22, 2015
Start date December 2012
Est. completion date December 2015

Study information

Verified date December 2015
Source Minneapolis Medical Research Foundation
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this project is to determine the levels of stress biomarkers associated with severe pain, agitation from intoxication or psychosis, and excited delirium at various levels of the disease in order to compare them to pre-clinical models of law enforcement encounters. We hypothesize that the serum catecholamines and markers of metabolic acidosis will worsen with the duration and severity of agitation among agitated patients and will not worsen among patients with severe pain who are not agitated.

Specific Aims

- To assess the prevalence of patients undergoing treatment for agitation from any cause requiring restraint or sedation.

- To assess the prevalence of excited delirium in the emergency department.

- To determine the difference in serum total catecholamines, serum dopamine, serum epinephrine, serum norepinephrine, heart rate, systolic blood pressure, mean arterial pressure, mortality, and disposition among patients with agitation requiring restraint, including excited delirium and patients with severe pain from extremity fractures.

- To describe changes in stress biomarkers among patients with changing levels of agitation as determined by the Altered Mental Status scale.


Description:

In this study, we propose to study Emergency Department patients under physiologic stress from severe pain, agitation, drug overdose, and excited delirium in order to compare markers of acidosis in patients at risk for unexplained-in-custody-death (UICD) in order to determine the relationship of these markers to what has been found in simulated law enforcement encounters. This information will help clarify the levels of stress associated with arrest and restraint conditions, allowing us to determine what aspects and levels of stress may be associated with the fatal mechanisms of UICD, and to identify markers that would inform death investigators of the mechanism of UICD. At the conclusion of this project, we will be able to report details explaining the relationship of the physiologic and metabolic effects of stress from restraint in excited delirium to other peri-arrest conditions and our previous work in simulated law enforcement encounters.


Recruitment information / eligibility

Status Completed
Enrollment 1322
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Agitation Group Inclusion Criteria:

- Patients with agitation as defined by an Altered Mental Status Score of >1, and who are in restraints or are given sedatives for treatment of agitation.

Agitation Group Exclusion Criteria:

- Less than 18 years of age

- Suspected or confirmed pregnancy

Pain Group Inclusion Criteria:

- Patients with an extremity fracture who report their pain as severe.

Pain Group Exclusion Criteria:

- Less than 18 years of age

- Suspected or confirmed pregnancy

- Prisoner

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Hennepin County Medical Center Minneapolis Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Minneapolis Medical Research Foundation U.S. Department of Justice

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Altered Mental Status Score Assessed every five minutes, from enrollment until discharge from the emergency department, an expected average time of 4 hours No
Primary Change in Visual Analog Scale Pain Score Assessed every five minutes, from enrollment until discharge from the emergency department, an expected average time of 4 hours No
Primary Change in Serum Total Catecholamines Serum dopamine, serum epinephrine, and serum norepinephrine. Assessed every 30 minutes, from enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Length of Hospital Stay Assessed at time of discharge from the hospital, an expected average of 4 hours post enrollment. No
Secondary Mortality Observed for 1 year post study enrollment No
Secondary Complications Observed for 1 year post study enrollment No
Secondary Change in Heart Rate Observed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Change in Systolic Blood Pressure Observed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Change in Mean Arterial Pressure Observed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Disposition Assessed at discharge from the emergency department, an expected average of 4 hours post enrollment. No
Secondary Change in Body Temperature Observed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Change in end tidal carbon dioxide Assessed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
Secondary Change in Oxygen Saturation Observed from time of enrollment until discharge from the emergency department, an expected average time of 4 hours No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care